Standard co-folding models struggle with induced proximity because public databases like the PDB lack sufficient training data for multi-protein complexes. Because dynamic multi-protein complexes take on endless conformations, standard AI models become overconfident and inaccurate. To solve this, Protai generates proprietary structural proteomics data that maps physical distances and conformations, enabling accurate modeling of complexes that can be targeted by molecular glues and PROTACs.
Transitioning from tech to biology requires discarding the Silicon Valley playbook of taking shortcuts and breaking things, because biological systems simply fail when rushed. However, founders must still align slower biological timelines with the exponential expectations of venture capital clocks. The critical skill is cutting losses rapidly, as late pivots in biology become far more expensive than in pure software.
TechBio platform companies offer multiple shots on goal rather than a single clinical asset, creating a risk profile distinct from traditional biotech. While tech investors often accept lower linear upside, successful drug platforms can deliver hundredfold step-function revenue leaps. To balance this unique dynamic of higher biological risk against massive economic payoff, founders must assemble investor syndicates that deliberately pair tech and life sciences expertise.
Despite competitors raising billions of dollars in the AI drug discovery sector, massive capital alone does not guarantee superior models. Many well-funded firms rely on retraining algorithms using the same publicly available crystal structure data. Generating unique, specialized experimental data at scale allows a lean startup to build more accurate predictive models while consuming a fraction of the funding.